Banyan Biomarkers Works with Emory University to Analyze Biomarkers in the Clinical Trial of Progesterone in Traumatic Brain Injury
8/4/2011 7:59:14 AM
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. will partner with Emory University through a grant from the National Institutes of Health to measure biomarkers in the blood of traumatic brain injury (TBI) patients. The five-year grant of $2.2 million was awarded to Michael Frankel, MD, Professor of Neurology at Emory School of Medicine, with partners Banyan Biomarkers, Inc., the Medical University of South Carolina, the University of Pittsburgh and the University of Michigan. The research team will study biomarkers in the blood of TBI patients enrolled in the phase III clinical trial, ProTECT III (Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment), which is assessing the efficacy of progesterone in the treatment of TBI.
comments powered by